A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Inclusion criteria

• Subjects ≥18 years of age
• Pathologically documented, locally-advanced or metastatic solid malignancy with NRAS or KRAS mutation
• At least one target lesion that can be measured per RECIST version 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function (bone marrow, hepatic, renal, cardiovascular)
• Documented disease progression despite appropriate prior standard therapies or subjects for whom no standard therapy exists for their tumor type and disease stage
• Reproductive criteria (as defined in the protocol)

Exclusion criteria

• Subjects with symptomatic central nervous system (CNS) metastases
• History of another primary malignancy, with the exception of locally excised nonmelanoma skin cancer and carcinoma in situ of uterine cervix
• Known active hepatitis B infection or hepatitis C infection
• Known pre-existing interstitial lung disease
• Known diagnosis of human immunodeficiency virus (HIV) infection
• History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy; or known risk factors for RVO or central serous retinopathy
• Any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the Investigator, Sponsor, or contract research organization, could affect the subject's participation in the study
• Impaired cardiac function or clinically significant cardiac diseases
• Previous treatment with RAS or MEK targeting agents
• Chemotherapy, biologic therapy, immunotherapy, radiotherapy, or investigational agents within 5 half-lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study treatment